LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.
The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met.
advertisement
AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT
Next article： In age of alternative facts, a scholarly course on calling out crap
Next article： In age of alternative facts, a scholarly course on calling out crap
